Acute Kidney Injury in Adult Patients Supported by VA-ECMO

Overview

Post-cardiotomy cardiogenic shock (PCCS) occurs in 2-6% of patients undergoing cardiac surgery, and 1% of cardiac surgery patients will require mechanical circulatory support using Veno-Arterial ExtraCorporeal Membrane Oxygenation (VA-ECMO). Acute Kidney Injury is a frequent complication in this population and negatively impacts the survival. We aimed to determine whether the timing of ECMO implantation influence the renal prognosis of these patients.

Full Title of Study: “Risk Factors and Prognosis of Acute Kidney Injury in Peri Operative Cardiac Surgery Adult Patients Supported by VA-ECMO”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: May 5, 2019

Interventions

  • Other: No intervention
    • No intervention

Arms, Groups and Cohorts

  • Group 1
    • Patients admitted in our unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
  • Group 2
    • Patients admitted in our unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
  • Group 3
    • Patients admitted in our unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI

Clinical Trial Outcome Measures

Primary Measures

  • Occurrence of a stage 3 AKI
    • Time Frame: Day 10 after ECMO implantation
    • Stage 3 according to the Kidney Disease: Improving Global Outcomes (KDIGO) group

Secondary Measures

  • Mortality at Day 30
    • Time Frame: Day 30 after ECMO implantation
    • Mortality
  • Mortality at 6 months
    • Time Frame: 6 months after ECMO implantation
    • Mortality

Participating in This Clinical Trial

Inclusion Criteria

  • All patients admitted in post-operative of cardiac surgery
  • Assisted by VA-ECMO

Exclusion Criteria

  • Chronic hemodialysis
  • Death occurring within the first 48 hours of VA-ECMO implantation
  • Multiple VA-ECMO during the same hospitalization.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Groupe Hospitalier Pitie-Salpetriere
  • Provider of Information About this Clinical Study
    • Principal Investigator: Adrien BouglĂ©, Head of Surgical Intensive Care Unit – Groupe Hospitalier Pitie-Salpetriere

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.